🇺🇸 FDA
Pipeline program

rituximab

199/15038

Phase 2 small_molecule completed

Quick answer

rituximab for Purpura, Thrombocytopenic, Idiopathic is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Purpura, Thrombocytopenic, Idiopathic
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials